This article is 3 years old
European efforts to assess Russia’s Sputnik V vaccine stymied by data gaps
The developers of Russia’s Sputnik V coronavirus vaccine have repeatedly failed to provide data that regulators deem to be standard requirements of the drug approval process.
This is according to five people with knowledge of European efforts to assess the drug, providing new insight into Russia's struggle to win foreign acceptance of its product.
Reuters reported last month that the European Medicines Agency (EMA)’s review of the drug’s safety and efficacy was delayed because...
Verifying user
RM12.50 / month
- Unlimited access to award-winning journalism
- Comment and share your opinions on all our articles
- Gift interesting stories to your friends
- Tax deductable